

# ForPatients

by Roche

Triple Negative Breast Cancer Breast Cancer

## A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

**Trial Status**  
Completed

**Trial Runs In**  
40 Countries

**Trial Identifier**  
NCT02425891 2014-005490-37  
WO29522

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This multicenter, randomized, double-blind study will evaluate the efficacy, safety, and pharmacokinetics of atezolizumab (MPDL3280A) administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC). The safety of single-agent nab-paclitaxel has been determined in previous studies of participants with mBC and the safety data to date suggest that atezolizumab can be safely combined with standard chemotherapy agents.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT02425891 2014-005490-37 WO29522**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---